Constipation Drugs Don’t Need CV Outcomes Studies, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca, Nektar, Salix and Progenics may avoid regulatory hurdle after advisory committee concludes that weak cardiovascular safety signal seen with Cubist’s opioid receptor antagonist Entereg does not justify mandatory outcomes trials.